Clinical and histopathological factors such as lymph node status, tumor size, histological grade, age, and expression of estrogen receptor (ER) and Her2 have traditionally guided treatment decisions of patients with operable breast cancer [1,2]. This evidence concerns the gene ESR1 and breast cancer.